FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

ZTS

ZoetisNYSE · Pharmaceuticals · Health Care
Previous close
79.72
Change
+0.92 / +1.17%
FinDog View
Neutral
52-Week Range ?
68.77 – 145.04
P/E (TTM) ?
12.3
Forward P/E ?
11.4
Based on consensus earnings for the next 12 months
Market Cap
$33.5B
1M
+14.16%
S&P 500 −0.91% over same period
Volume / Avg Volume
4.1M / 3.2M
1.29× average
Latest earnings analysisFY2026 Q2Reported 2026-08-06

Zoetis Q2 FY2026: flat revenue, guidance cut hard

Zoetis reported flat second-quarter revenue of $2.468 billion and adjusted EPS of $1.87, a hair below the $1.8742 consensus, then cut full-year revenue and EPS guidance hard. The read-through is simple: U.S. companion animal demand is the problem, livestock and international sales are the offset, and the balance sheet leaves little room for a long slump.

Read the full analysis →
Revenue$2.47BYoY −0.20%
EPS (non-GAAP)$1.87In lineest. $1.87
Next-quarter revenue guidance$9.22B ±1.1%YoY +273.60%
Next-day move−5.97%

Price History

Closing price · USD1M6M1Y5Y
6080100120140160EFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 EarningsEFY25 Q3 Earnings2025-102026-012026-052026-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 12.71M6M1Y5Y
111213142026-092026-102026-102026-102026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-05
in 4 days · Pre-market
Consensus EPS
$1.52
Last quarter EPS $1.87
Avg. next-day move over the last 6 reports
±3.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 6 of its 5-year rangeCheap
5-year range 12.3 – 39.3 · Median 29.9
Last 4 quarters: $3.6B in buybacks + $0 in dividends, 10.88% of market cap combined
P/E (TTM)
12.3
P/B
10.2
P/S
3.4
Dividend Yield
1.64%
Earnings Reaction
Over the last 6 reports, the stock moved ±3.2% on average on the first trading day after, rising 3 times
Most recent −5.97%
Volatility & Correlation
1-year beta 0.48 · Correlation with S&P 500 0.16Low beta
Annualized volatility 38% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q22.47−0.2%72.7%—0.690.541.65
FY2026 Q12.26+2.9%71.7%—0.600.291.42
FY2025 Q42.40+3.4%70.7%—0.620.731.42
FY2025 Q32.40+0.5%71.5%—0.720.761.63
FY2025 Q22.47+4.8%73.2%—0.730.461.63
FY2025 Q12.20+0.4%71.9%—0.600.341.34
FY2024 Q42.32+4.7%69.5%—0.580.691.29
FY2024 Q32.39+11.0%70.6%—0.680.781.50
FY2024 Q22.36+8.3%71.7%—0.620.371.37
FY2024 Q12.19+9.5%70.6%—0.600.461.31
FY2023 Q42.21+8.5%67.1%—0.530.701.14
FY2023 Q32.15+7.4%70.3%—0.600.581.29

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView